MUSC Hollings Cancer Center

Philip H. Howe, PhD

Dr. Philip H. Howe joined the Hollings Cancer Center in 2011 and holds the Hans and Helen Koebig Chair in Clinical Oncology.  He is also Professor and Chair of Biochemistry & Molecular Biology.  Dr. Howe has an outstanding record of scientific achievements and has maintained extramural funding from multiple sources throughout his research career.  His research is focused on transforming growth factor b (TGFb) signaling pathways in mediating the epithelial-mesenchymal transition (EMT) in epithelium and apoptosis in developing B-lymphocytes.  His lab was instrumental in the identification of non-canonical (non-Smad) TGFb signaling pathways, the role of the pro-apoptotic Bim protein in mediating apoptosis, the role of disabled-2 (Dab2) as an adaptor in TGFb signaling and in mediating the EMT response, and more recently the translational regulation of EMT-regulated mRNA transcripts by TGFb.  These recent studies have used a variety of models including zebrafish and animal cancer models to demonstrate that TGFb-mediated translational regulation plays an integral role during metastatic progression and establishment of stem cell characteristics in breast epithelium.

Learn more about Philip H. Howe, PhD...

 
 
 

* This website is best viewed in Firefox or Chrome internet browsers.